Kymera Therapeutics (US:KYMR) — Company Overview, News & Financial Data
Kymera Therapeutics advances targeted protein degradation therapies for diseases, focusing on immuno-oncology and inflammatory conditions.
KYMRKymera Therapeutics
Company profile
About Kymera Therapeutics
Kymera Therapeutics (NASDAQ:KYMR) is a biotechnology firm focused on pioneering advances in targeted protein degradation (TPD) to address previously untreatable diseases. Utilizing its proprietary Pegasus platform, Kymera aims to harness the body's innate protein recycling machinery to degrade disease-causing proteins with a high degree of selectivity. The company's pipeline includes projects targeting various disorders, with a strong emphasis on immuno-oncology, inflammatory diseases, and fibrosis. Kymera is on a mission to transform the treatment landscape for patients through innovative science and strategic partnerships, aspiring to deliver a new class of highly effective therapies across multiple disease areas.
Snapshot
Public USOwnership
2015Year founded
207Employees
Massachusetts, United StatesHead office
Loading Map...
Global footprint
Operations
All Locations
United States
Products and/or services of Kymera Therapeutics
- Targeted Protein Degradation Platform: A technology platform designed to harness the body's natural protein degradation system to selectively eliminate disease-causing proteins.
- KT-474: An orally bioavailable IRAK4 degrader targeting immune-inflammatory diseases such as atopic dermatitis and hidradenitis suppurativa.
- KT-333: A STAT3 degrader aimed at treating hematologic malignancies and solid tumors by disrupting critical cancer cell signaling pathways.
- KT-413: An IRAKIMiD bifunctional molecule targeting MYD88-mutant B-cell malignancies by combining IRAK4 degradation and IMiD therapy.
- STAT3 Degrader Program: "Focused on developing selective degraders of STAT3 to combat various forms of cancer.
- PI3Kd Degrader Program: Designed to selectively degrade PI3Kd, a protein kinase implicated in a wide range of hematologic malignancies.
Kymera Therapeutics executive team
- Dr. Bruce L. Booth DPHIL, Ph.D.Co-Founder & Independent Chairman
- Dr. Nello Mainolfi M.D., Ph.D.Co-Founder, President, CEO & Director
- Mr. Bruce N. Jacobs CFAChief Financial Officer
- Dr. Jeremy G. Chadwick Ph.D.Chief Operating Officer
- Dr. Jared A. Gollob M.D.Chief Medical Officer
- Ms. Justine E. KoenigsbergVice President of Investor Relations
- Mr. Brian R. Adams J.D.Chief Legal Officer & Corporate Secretary
- Ms. Karen WeisbachHead of People & Culture
- Dr. Juliet Williams B.A Ph.D.Head of Research
- Mr. Noah Goodman M.B.A.Chief Business Officer